PTGFRN and Alzheimer disease: The results indicated that astrocyte-specific molecules were enriched in AD compared to MCI, and HSPA1A, NPEPPS, and PTGFRN can be applied to monitor the progression of MCI to AD (Muraoka et al., 2020b).